Welcome to our dedicated page for Kala Pharmaceuticals news (Ticker: KALA), a resource for investors and traders seeking the latest updates and insights on Kala Pharmaceuticals stock.
Kala Pharmaceuticals Inc (NASDAQ: KALA) is a clinical-stage biopharmaceutical company pioneering novel therapies for severe ocular diseases through its proprietary MSC-S platform and nanoparticle drug formulations. This page provides authorized updates on KALA's clinical developments, regulatory milestones, and research advancements.
Investors and researchers will find verified press releases covering Phase 2/3 trial progress for lead candidate KPI-012 in PCED treatment, FDA designations for rare disease therapies, and peer-reviewed study publications. All content is curated to meet strict journalistic standards for accuracy in biopharmaceutical reporting.
The news archive includes updates on corneal healing therapies, retinal disorder research collaborations, intellectual property developments, and scientific conference presentations. Content is organized chronologically with clear sourcing to enable efficient tracking of the company's progress in ocular regenerative medicine.
Bookmark this page for direct access to Kala Pharmaceuticals' official announcements, including trial enrollment updates, partnership disclosures with academic institutions, and manufacturing scale-up progress. Check regularly for the latest validated information on this innovative developer of first-in-class ocular biologics.
Kala Pharmaceuticals (NASDAQ:KALA), a biopharmaceutical firm specializing in ocular therapies, will report its second quarter 2021 financial results on August 5, 2021. The company will also host a conference call at 8:00 a.m. ET to discuss the results and provide a business update. Kala's products include EYSUVIS for dry eye disease and INVELTYS for post-operative inflammation. The company leverages its proprietary AMPPLIFY mucus-penetrating particle technology to enhance drug delivery.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced the granting of non-statutory stock options to 16 new employees as inducement awards outside its 2017 Equity Incentive Plan. A total of 92,000 stock options were granted on July 15, 2021, with an exercise price of $4.01 per share, reflecting the closing price on that date. These options will vest over four years, with 25% vesting after the first year. This move is part of the company's strategy to attract and retain talent in its ongoing development of innovative ocular therapies.
Kala Pharmaceuticals (NASDAQ: KALA) announced the grant of non-statutory stock options to five new employees, totaling 64,500 shares. This award was made outside the 2017 Equity Incentive Plan in compliance with NASDAQ Listing Rule 5635(c)(4). The options, which vest over four years, were approved by the Compensation Committee and have an exercise price of $5.70 per share, reflecting the closing stock price on June 15, 2021. This move is aimed at incentivizing new hires as the company continues its focus on developing innovative therapies for eye diseases.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced that OptumRx, a major pharmacy benefit manager in the U.S., has included EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% on its commercial formularies, effective May 21, 2021. This addition allows more than 88 million people with commercial health insurance access to EYSUVIS, furthering Kala's goal of widespread market access. EYSUVIS, approved by the FDA in October 2020, is the first prescription therapy specifically for short-term dry eye disease treatment. The company aims to expand payer coverage through ongoing efforts with health plans.
Kala Pharmaceuticals (NASDAQ: KALA) will present at the Jefferies 2021 Virtual Healthcare Conference. The management team is scheduled for a fireside chat on June 3, 2021, at 10:00 am ET. Investors can access the live webcast and the archived recording through the Events section of the Kala website.
Kala focuses on innovative therapies for eye diseases, utilizing its AMPPLIFY® technology. Key products include EYSUVIS® for dry eye treatment and INVELTYS® for post-operative inflammation. The company also has a pipeline targeting unmet medical needs in ocular health.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company specializing in innovative eye disease therapies, will present at the BofA Securities 2021 Healthcare Conference. The management team is set to participate in a Fireside Chat on May 13, 2021, at 4:15 pm ET. Investors can access the live webcast and a recording afterward via the 'Events' section of the Kala website. The company's products include EYSUVIS® and INVELTYS®, which utilize AMPPLIFY® technology, addressing dry eye disease and post-operative inflammation.
Kala Pharmaceuticals (NASDAQ:KALA) reported its Q1 2021 financial results, highlighting a net loss of $30.4 million or $0.49 per share, versus a $22 million loss in Q1 2020. Product revenues reached $3.3 million, driven by EYSUVIS and INVELTYS sales. The company has secured coverage for approximately 43% of commercial lives and plans to expand its sales force from 91 to 125 by year-end. A new credit facility of up to $125 million was established to extend cash runway for at least two years. The company continues to progress its pipeline for treating eye diseases.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) will announce its first quarter 2021 financial results on May 5, 2021. A conference call will follow at 8:00 a.m. ET to discuss results and provide a business update. Dial-in numbers are 866-300-4091 (domestic) and 703-736-7433 (international) with conference ID 2777865. The company focuses on innovative therapies for eye diseases, utilizing its AMPPLIFY® drug delivery technology in products like EYSUVIS® for dry eye and INVELTYS® for postoperative inflammation. Visit kalarx.com for more information.
Kala Pharmaceuticals (NASDAQ: KALA) announced the granting of stock options to four new employees as part of inducement awards outside the Company’s 2017 Equity Incentive Plan, in line with NASDAQ Rule 5635(c)(4). The options, totaling 32,200 shares, were granted on March 15, 2021, with an exercise price set at $7.54 per share, coinciding with the closing stock price on that date. These options have a ten-year term, vesting over four years, subject to each employee's continued service.
Kala Pharmaceuticals (NASDAQ:KALA) announced that Cigna has added its product EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% to its commercial formulary as a preferred brand, effective May 15, 2021. This addition is expected to enhance patient access to EYSUVIS, which is the first prescription drug approved for the short-term treatment of dry eye disease symptoms. The company aims to engage with additional health plans to expand coverage for this therapy, enhancing its market presence.
